nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—CYP2D6—Fingolimod—multiple sclerosis	0.0645	0.261	CbGbCtD
Lisuride—HTR1B—trigeminal nucleus—multiple sclerosis	0.054	0.166	CbGeAlD
Lisuride—HTR1D—trigeminal nucleus—multiple sclerosis	0.0523	0.161	CbGeAlD
Lisuride—CYP3A4—Fingolimod—multiple sclerosis	0.041	0.166	CbGbCtD
Lisuride—HTR1D—meninx—multiple sclerosis	0.0347	0.107	CbGeAlD
Lisuride—CYP3A4—Methylprednisolone—multiple sclerosis	0.0264	0.107	CbGbCtD
Lisuride—HTR2A—trigeminal nucleus—multiple sclerosis	0.026	0.0799	CbGeAlD
Lisuride—CYP3A4—Triamcinolone—multiple sclerosis	0.02	0.0811	CbGbCtD
Lisuride—CYP3A4—Mitoxantrone—multiple sclerosis	0.0193	0.078	CbGbCtD
Lisuride—CYP3A4—Betamethasone—multiple sclerosis	0.0172	0.0696	CbGbCtD
Lisuride—CYP3A4—Prednisolone—multiple sclerosis	0.017	0.0686	CbGbCtD
Lisuride—CYP3A4—Prednisone—multiple sclerosis	0.016	0.0648	CbGbCtD
Lisuride—CYP2D6—Dexamethasone—multiple sclerosis	0.0157	0.0636	CbGbCtD
Lisuride—HTR1B—trigeminal nerve—multiple sclerosis	0.0142	0.0436	CbGeAlD
Lisuride—HTR1D—trigeminal nerve—multiple sclerosis	0.0137	0.0423	CbGeAlD
Lisuride—CYP3A4—Dexamethasone—multiple sclerosis	0.01	0.0405	CbGbCtD
Lisuride—Pulmonary fibrosis—Cladribine—multiple sclerosis	0.00705	0.039	CcSEcCtD
Lisuride—HTR2A—trigeminal nerve—multiple sclerosis	0.00682	0.021	CbGeAlD
Lisuride—DRD1—nerve—multiple sclerosis	0.00639	0.0197	CbGeAlD
Lisuride—HTR2A—pons—multiple sclerosis	0.0048	0.0148	CbGeAlD
Lisuride—Pleurisy—Methotrexate—multiple sclerosis	0.00416	0.023	CcSEcCtD
Lisuride—DRD2—nerve—multiple sclerosis	0.00377	0.0116	CbGeAlD
Lisuride—ADRA2A—peripheral nervous system—multiple sclerosis	0.00376	0.0116	CbGeAlD
Lisuride—HTR2A—pineal body—multiple sclerosis	0.00343	0.0106	CbGeAlD
Lisuride—HTR2A—peripheral nervous system—multiple sclerosis	0.00319	0.00983	CbGeAlD
Lisuride—Weight decreased—Fingolimod—multiple sclerosis	0.00311	0.0172	CcSEcCtD
Lisuride—Dementia—Prednisone—multiple sclerosis	0.00296	0.0164	CcSEcCtD
Lisuride—DRD1—brainstem—multiple sclerosis	0.00274	0.00844	CbGeAlD
Lisuride—Cardiac disorder—Fingolimod—multiple sclerosis	0.00255	0.0141	CcSEcCtD
Lisuride—Disorientation—Cladribine—multiple sclerosis	0.00252	0.0139	CcSEcCtD
Lisuride—Angiopathy—Fingolimod—multiple sclerosis	0.00249	0.0138	CcSEcCtD
Lisuride—HTR2A—nerve—multiple sclerosis	0.00249	0.00767	CbGeAlD
Lisuride—Mediastinal disorder—Fingolimod—multiple sclerosis	0.00248	0.0137	CcSEcCtD
Lisuride—Pericardial effusion—Methotrexate—multiple sclerosis	0.00248	0.0137	CcSEcCtD
Lisuride—Dementia—Methotrexate—multiple sclerosis	0.00248	0.0137	CcSEcCtD
Lisuride—Mental disorder—Fingolimod—multiple sclerosis	0.00241	0.0133	CcSEcCtD
Lisuride—Pericarditis—Methotrexate—multiple sclerosis	0.00235	0.013	CcSEcCtD
Lisuride—Pulmonary fibrosis—Methotrexate—multiple sclerosis	0.00231	0.0128	CcSEcCtD
Lisuride—HTR1B—brainstem—multiple sclerosis	0.00222	0.00684	CbGeAlD
Lisuride—DRD4—brain—multiple sclerosis	0.00218	0.00672	CbGeAlD
Lisuride—HTR1D—brainstem—multiple sclerosis	0.00215	0.00662	CbGeAlD
Lisuride—HTR2C—brainstem—multiple sclerosis	0.00213	0.00656	CbGeAlD
Lisuride—Palpitations—Fingolimod—multiple sclerosis	0.00211	0.0117	CcSEcCtD
Lisuride—Cough—Fingolimod—multiple sclerosis	0.00209	0.0116	CcSEcCtD
Lisuride—DRD3—nervous system—multiple sclerosis	0.00201	0.00618	CbGeAlD
Lisuride—Infection—Fingolimod—multiple sclerosis	0.00194	0.0107	CcSEcCtD
Lisuride—DRD3—central nervous system—multiple sclerosis	0.00193	0.00595	CbGeAlD
Lisuride—Nervous system disorder—Fingolimod—multiple sclerosis	0.00191	0.0106	CcSEcCtD
Lisuride—DRD5—nervous system—multiple sclerosis	0.00188	0.00579	CbGeAlD
Lisuride—Abdominal discomfort—Cladribine—multiple sclerosis	0.00187	0.0103	CcSEcCtD
Lisuride—DRD5—central nervous system—multiple sclerosis	0.00181	0.00557	CbGeAlD
Lisuride—HTR1A—brainstem—multiple sclerosis	0.00179	0.00552	CbGeAlD
Lisuride—DRD1—midbrain—multiple sclerosis	0.00175	0.00538	CbGeAlD
Lisuride—Dyspnoea—Fingolimod—multiple sclerosis	0.00174	0.00964	CcSEcCtD
Lisuride—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00169	0.00933	CcSEcCtD
Lisuride—Fatigue—Fingolimod—multiple sclerosis	0.00168	0.00932	CcSEcCtD
Lisuride—DRD2—brainstem—multiple sclerosis	0.00162	0.00499	CbGeAlD
Lisuride—DRD2—retina—multiple sclerosis	0.00156	0.00481	CbGeAlD
Lisuride—ADRA1B—nervous system—multiple sclerosis	0.00154	0.00475	CbGeAlD
Lisuride—Oedema peripheral—Cladribine—multiple sclerosis	0.00153	0.0085	CcSEcCtD
Lisuride—DRD3—brain—multiple sclerosis	0.00153	0.00472	CbGeAlD
Lisuride—Abdominal discomfort—Azathioprine—multiple sclerosis	0.00152	0.0084	CcSEcCtD
Lisuride—ADRA1D—nervous system—multiple sclerosis	0.00151	0.00464	CbGeAlD
Lisuride—HTR2C—medulla oblongata—multiple sclerosis	0.00149	0.00457	CbGeAlD
Lisuride—ADRA1B—central nervous system—multiple sclerosis	0.00148	0.00457	CbGeAlD
Lisuride—ADRA1D—central nervous system—multiple sclerosis	0.00145	0.00447	CbGeAlD
Lisuride—Cardiac disorder—Cladribine—multiple sclerosis	0.00145	0.008	CcSEcCtD
Lisuride—DRD5—brain—multiple sclerosis	0.00144	0.00443	CbGeAlD
Lisuride—DRD1—nervous system—multiple sclerosis	0.00144	0.00442	CbGeAlD
Lisuride—HTR1B—midbrain—multiple sclerosis	0.00142	0.00436	CbGeAlD
Lisuride—Angiopathy—Cladribine—multiple sclerosis	0.00141	0.00782	CcSEcCtD
Lisuride—Immune system disorder—Cladribine—multiple sclerosis	0.00141	0.00779	CcSEcCtD
Lisuride—Mediastinal disorder—Cladribine—multiple sclerosis	0.0014	0.00777	CcSEcCtD
Lisuride—Asthenia—Fingolimod—multiple sclerosis	0.0014	0.00775	CcSEcCtD
Lisuride—DRD1—central nervous system—multiple sclerosis	0.00138	0.00426	CbGeAlD
Lisuride—HTR1B—spinal cord—multiple sclerosis	0.00138	0.00425	CbGeAlD
Lisuride—Dehydration—Mitoxantrone—multiple sclerosis	0.00138	0.00762	CcSEcCtD
Lisuride—HTR1D—midbrain—multiple sclerosis	0.00137	0.00422	CbGeAlD
Lisuride—Mental disorder—Cladribine—multiple sclerosis	0.00136	0.00756	CcSEcCtD
Lisuride—HTR2C—midbrain—multiple sclerosis	0.00136	0.00418	CbGeAlD
Lisuride—Malnutrition—Cladribine—multiple sclerosis	0.00136	0.00751	CcSEcCtD
Lisuride—Pleural effusion—Methotrexate—multiple sclerosis	0.00133	0.00734	CcSEcCtD
Lisuride—HTR2C—spinal cord—multiple sclerosis	0.00132	0.00408	CbGeAlD
Lisuride—Dizziness—Fingolimod—multiple sclerosis	0.00129	0.00715	CcSEcCtD
Lisuride—Headache—Fingolimod—multiple sclerosis	0.00122	0.00677	CcSEcCtD
Lisuride—Cough—Cladribine—multiple sclerosis	0.00118	0.00655	CcSEcCtD
Lisuride—ADRA1B—brain—multiple sclerosis	0.00118	0.00363	CbGeAlD
Lisuride—HTR1B—nervous system—multiple sclerosis	0.00116	0.00358	CbGeAlD
Lisuride—Weight increased—Mitoxantrone—multiple sclerosis	0.00116	0.00645	CcSEcCtD
Lisuride—Weight decreased—Mitoxantrone—multiple sclerosis	0.00116	0.00641	CcSEcCtD
Lisuride—ADRA1D—brain—multiple sclerosis	0.00115	0.00355	CbGeAlD
Lisuride—Anxiety—Cladribine—multiple sclerosis	0.00115	0.00637	CcSEcCtD
Lisuride—Immune system disorder—Azathioprine—multiple sclerosis	0.00114	0.00633	CcSEcCtD
Lisuride—HTR1A—midbrain—multiple sclerosis	0.00114	0.00352	CbGeAlD
Lisuride—Mediastinal disorder—Azathioprine—multiple sclerosis	0.00114	0.00632	CcSEcCtD
Lisuride—HTR1D—nervous system—multiple sclerosis	0.00113	0.00347	CbGeAlD
Lisuride—HTR1B—central nervous system—multiple sclerosis	0.00112	0.00345	CbGeAlD
Lisuride—HTR2C—nervous system—multiple sclerosis	0.00112	0.00344	CbGeAlD
Lisuride—Confusional state—Cladribine—multiple sclerosis	0.00112	0.00618	CcSEcCtD
Lisuride—HTR1A—spinal cord—multiple sclerosis	0.00112	0.00343	CbGeAlD
Lisuride—Infection—Cladribine—multiple sclerosis	0.0011	0.00609	CcSEcCtD
Lisuride—ADRA2C—medulla oblongata—multiple sclerosis	0.0011	0.00338	CbGeAlD
Lisuride—DRD1—brain—multiple sclerosis	0.0011	0.00338	CbGeAlD
Lisuride—ADRB1—nervous system—multiple sclerosis	0.0011	0.00337	CbGeAlD
Lisuride—Sweating—Mitoxantrone—multiple sclerosis	0.00109	0.00605	CcSEcCtD
Lisuride—HTR1D—central nervous system—multiple sclerosis	0.00109	0.00334	CbGeAlD
Lisuride—Nervous system disorder—Cladribine—multiple sclerosis	0.00109	0.00601	CcSEcCtD
Lisuride—Tachycardia—Cladribine—multiple sclerosis	0.00108	0.00598	CcSEcCtD
Lisuride—HTR2C—central nervous system—multiple sclerosis	0.00107	0.00331	CbGeAlD
Lisuride—Hyperhidrosis—Cladribine—multiple sclerosis	0.00107	0.00592	CcSEcCtD
Lisuride—HTR2A—brainstem—multiple sclerosis	0.00107	0.00329	CbGeAlD
Lisuride—Anorexia—Cladribine—multiple sclerosis	0.00105	0.00584	CcSEcCtD
Lisuride—ADRB1—central nervous system—multiple sclerosis	0.00105	0.00325	CbGeAlD
Lisuride—HTR2B—nervous system—multiple sclerosis	0.00105	0.00323	CbGeAlD
Lisuride—DRD2—midbrain—multiple sclerosis	0.00103	0.00318	CbGeAlD
Lisuride—HTR2A—retina—multiple sclerosis	0.00103	0.00317	CbGeAlD
Lisuride—HTR2B—central nervous system—multiple sclerosis	0.00101	0.00311	CbGeAlD
Lisuride—ADRA2C—midbrain—multiple sclerosis	0.001	0.00309	CbGeAlD
Lisuride—Insomnia—Cladribine—multiple sclerosis	0.001	0.00554	CcSEcCtD
Lisuride—Dyspnoea—Cladribine—multiple sclerosis	0.000987	0.00546	CcSEcCtD
Lisuride—Somnolence—Cladribine—multiple sclerosis	0.000984	0.00545	CcSEcCtD
Lisuride—ADRA2C—spinal cord—multiple sclerosis	0.00098	0.00302	CbGeAlD
Lisuride—CYP2D6—brainstem—multiple sclerosis	0.000974	0.003	CbGeAlD
Lisuride—Decreased appetite—Cladribine—multiple sclerosis	0.000962	0.00533	CcSEcCtD
Lisuride—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000955	0.00529	CcSEcCtD
Lisuride—Weight increased—Prednisolone—multiple sclerosis	0.000955	0.00529	CcSEcCtD
Lisuride—Fatigue—Cladribine—multiple sclerosis	0.000954	0.00528	CcSEcCtD
Lisuride—Constipation—Cladribine—multiple sclerosis	0.000946	0.00524	CcSEcCtD
Lisuride—HTR1A—nervous system—multiple sclerosis	0.00094	0.00289	CbGeAlD
Lisuride—Feeling abnormal—Cladribine—multiple sclerosis	0.000912	0.00505	CcSEcCtD
Lisuride—HTR1A—central nervous system—multiple sclerosis	0.000905	0.00279	CbGeAlD
Lisuride—Infection—Azathioprine—multiple sclerosis	0.000894	0.00495	CcSEcCtD
Lisuride—HTR1B—brain—multiple sclerosis	0.00089	0.00274	CbGeAlD
Lisuride—HTR1A—cerebellum—multiple sclerosis	0.000884	0.00272	CbGeAlD
Lisuride—Weight increased—Triamcinolone—multiple sclerosis	0.000878	0.00486	CcSEcCtD
Lisuride—ADRA2A—medulla oblongata—multiple sclerosis	0.000877	0.0027	CbGeAlD
Lisuride—Weight increased—Methylprednisolone—multiple sclerosis	0.000876	0.00485	CcSEcCtD
Lisuride—HTR1D—brain—multiple sclerosis	0.000862	0.00265	CbGeAlD
Lisuride—HTR2C—brain—multiple sclerosis	0.000853	0.00263	CbGeAlD
Lisuride—DRD2—nervous system—multiple sclerosis	0.000849	0.00261	CbGeAlD
Lisuride—ADRB1—brain—multiple sclerosis	0.000837	0.00258	CbGeAlD
Lisuride—ADRA2C—nervous system—multiple sclerosis	0.000825	0.00254	CbGeAlD
Lisuride—Sweating—Methylprednisolone—multiple sclerosis	0.000823	0.00456	CcSEcCtD
Lisuride—DRD2—central nervous system—multiple sclerosis	0.000817	0.00252	CbGeAlD
Lisuride—HTR2B—brain—multiple sclerosis	0.000802	0.00247	CbGeAlD
Lisuride—ADRA2A—midbrain—multiple sclerosis	0.000801	0.00247	CbGeAlD
Lisuride—DRD2—cerebellum—multiple sclerosis	0.000799	0.00246	CbGeAlD
Lisuride—Weight increased—Dexamethasone—multiple sclerosis	0.000797	0.00441	CcSEcCtD
Lisuride—Weight increased—Betamethasone—multiple sclerosis	0.000797	0.00441	CcSEcCtD
Lisuride—ADRA2C—central nervous system—multiple sclerosis	0.000795	0.00245	CbGeAlD
Lisuride—Asthenia—Cladribine—multiple sclerosis	0.000794	0.0044	CcSEcCtD
Lisuride—Weight decreased—Betamethasone—multiple sclerosis	0.000792	0.00439	CcSEcCtD
Lisuride—Weight decreased—Dexamethasone—multiple sclerosis	0.000792	0.00439	CcSEcCtD
Lisuride—ADRA2A—spinal cord—multiple sclerosis	0.000782	0.00241	CbGeAlD
Lisuride—Cough—Mitoxantrone—multiple sclerosis	0.000778	0.00431	CcSEcCtD
Lisuride—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000777	0.0043	CcSEcCtD
Lisuride—ADRA2C—cerebellum—multiple sclerosis	0.000777	0.00239	CbGeAlD
Lisuride—Hallucination—Methylprednisolone—multiple sclerosis	0.000767	0.00425	CcSEcCtD
Lisuride—Anxiety—Mitoxantrone—multiple sclerosis	0.000756	0.00419	CcSEcCtD
Lisuride—HTR2A—medulla oblongata—multiple sclerosis	0.000745	0.00229	CbGeAlD
Lisuride—Feeling abnormal—Azathioprine—multiple sclerosis	0.000741	0.00411	CcSEcCtD
Lisuride—Confusional state—Mitoxantrone—multiple sclerosis	0.000733	0.00406	CcSEcCtD
Lisuride—Dizziness—Cladribine—multiple sclerosis	0.000732	0.00405	CcSEcCtD
Lisuride—Infection—Mitoxantrone—multiple sclerosis	0.000723	0.004	CcSEcCtD
Lisuride—HTR1A—brain—multiple sclerosis	0.000718	0.00221	CbGeAlD
Lisuride—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000715	0.00396	CcSEcCtD
Lisuride—Tachycardia—Mitoxantrone—multiple sclerosis	0.00071	0.00393	CcSEcCtD
Lisuride—Vomiting—Cladribine—multiple sclerosis	0.000704	0.0039	CcSEcCtD
Lisuride—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000703	0.00389	CcSEcCtD
Lisuride—Angiopathy—Methylprednisolone—multiple sclerosis	0.000699	0.00387	CcSEcCtD
Lisuride—Hallucination—Betamethasone—multiple sclerosis	0.000697	0.00386	CcSEcCtD
Lisuride—Hallucination—Dexamethasone—multiple sclerosis	0.000697	0.00386	CcSEcCtD
Lisuride—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000696	0.00385	CcSEcCtD
Lisuride—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000695	0.00385	CcSEcCtD
Lisuride—Weight increased—Prednisone—multiple sclerosis	0.000694	0.00384	CcSEcCtD
Lisuride—Anorexia—Mitoxantrone—multiple sclerosis	0.000693	0.00384	CcSEcCtD
Lisuride—Headache—Cladribine—multiple sclerosis	0.000693	0.00384	CcSEcCtD
Lisuride—Weight decreased—Prednisone—multiple sclerosis	0.00069	0.00382	CcSEcCtD
Lisuride—HTR2A—midbrain—multiple sclerosis	0.000681	0.0021	CbGeAlD
Lisuride—Mental disorder—Methylprednisolone—multiple sclerosis	0.000675	0.00374	CcSEcCtD
Lisuride—Malnutrition—Methylprednisolone—multiple sclerosis	0.000671	0.00371	CcSEcCtD
Lisuride—HTR2A—spinal cord—multiple sclerosis	0.000665	0.00205	CbGeAlD
Lisuride—ADRA2A—nervous system—multiple sclerosis	0.000659	0.00203	CbGeAlD
Lisuride—Vertigo—Prednisolone—multiple sclerosis	0.000657	0.00364	CcSEcCtD
Lisuride—Syncope—Prednisolone—multiple sclerosis	0.000656	0.00363	CcSEcCtD
Lisuride—DRD2—brain—multiple sclerosis	0.000649	0.002	CbGeAlD
Lisuride—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000648	0.00359	CcSEcCtD
Lisuride—Somnolence—Mitoxantrone—multiple sclerosis	0.000647	0.00358	CcSEcCtD
Lisuride—Angiopathy—Dexamethasone—multiple sclerosis	0.000636	0.00352	CcSEcCtD
Lisuride—Angiopathy—Betamethasone—multiple sclerosis	0.000636	0.00352	CcSEcCtD
Lisuride—ADRA2A—central nervous system—multiple sclerosis	0.000634	0.00195	CbGeAlD
Lisuride—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000632	0.0035	CcSEcCtD
Lisuride—ADRA2C—brain—multiple sclerosis	0.000631	0.00194	CbGeAlD
Lisuride—Fatigue—Mitoxantrone—multiple sclerosis	0.000627	0.00347	CcSEcCtD
Lisuride—Constipation—Mitoxantrone—multiple sclerosis	0.000622	0.00344	CcSEcCtD
Lisuride—ADRA2A—cerebellum—multiple sclerosis	0.00062	0.00191	CbGeAlD
Lisuride—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000611	0.00338	CcSEcCtD
Lisuride—Hallucination—Prednisone—multiple sclerosis	0.000607	0.00336	CcSEcCtD
Lisuride—Vertigo—Triamcinolone—multiple sclerosis	0.000604	0.00334	CcSEcCtD
Lisuride—Syncope—Triamcinolone—multiple sclerosis	0.000603	0.00334	CcSEcCtD
Lisuride—Vertigo—Methylprednisolone—multiple sclerosis	0.000603	0.00334	CcSEcCtD
Lisuride—Syncope—Methylprednisolone—multiple sclerosis	0.000602	0.00333	CcSEcCtD
Lisuride—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000599	0.00332	CcSEcCtD
Lisuride—Dizziness—Azathioprine—multiple sclerosis	0.000595	0.00329	CcSEcCtD
Lisuride—Cough—Triamcinolone—multiple sclerosis	0.000587	0.00325	CcSEcCtD
Lisuride—Tachycardia—Prednisolone—multiple sclerosis	0.000582	0.00322	CcSEcCtD
Lisuride—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000577	0.00319	CcSEcCtD
Lisuride—Vomiting—Azathioprine—multiple sclerosis	0.000572	0.00317	CcSEcCtD
Lisuride—Anxiety—Methylprednisolone—multiple sclerosis	0.000569	0.00315	CcSEcCtD
Lisuride—Headache—Azathioprine—multiple sclerosis	0.000564	0.00312	CcSEcCtD
Lisuride—HTR2A—nervous system—multiple sclerosis	0.00056	0.00172	CbGeAlD
Lisuride—Dry mouth—Triamcinolone—multiple sclerosis	0.00056	0.0031	CcSEcCtD
Lisuride—Angiopathy—Prednisone—multiple sclerosis	0.000554	0.00307	CcSEcCtD
Lisuride—Confusional state—Methylprednisolone—multiple sclerosis	0.000552	0.00306	CcSEcCtD
Lisuride—Immune system disorder—Prednisone—multiple sclerosis	0.000551	0.00305	CcSEcCtD
Lisuride—Vertigo—Betamethasone—multiple sclerosis	0.000548	0.00304	CcSEcCtD
Lisuride—Vertigo—Dexamethasone—multiple sclerosis	0.000548	0.00304	CcSEcCtD
Lisuride—Syncope—Betamethasone—multiple sclerosis	0.000547	0.00303	CcSEcCtD
Lisuride—Syncope—Dexamethasone—multiple sclerosis	0.000547	0.00303	CcSEcCtD
Lisuride—Infection—Triamcinolone—multiple sclerosis	0.000545	0.00302	CcSEcCtD
Lisuride—Sweating—Methotrexate—multiple sclerosis	0.000545	0.00302	CcSEcCtD
Lisuride—Infection—Methylprednisolone—multiple sclerosis	0.000544	0.00301	CcSEcCtD
Lisuride—Insomnia—Prednisolone—multiple sclerosis	0.00054	0.00299	CcSEcCtD
Lisuride—HTR2A—central nervous system—multiple sclerosis	0.000539	0.00166	CbGeAlD
Lisuride—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000537	0.00297	CcSEcCtD
Lisuride—Tachycardia—Triamcinolone—multiple sclerosis	0.000536	0.00297	CcSEcCtD
Lisuride—Mental disorder—Prednisone—multiple sclerosis	0.000535	0.00296	CcSEcCtD
Lisuride—Tachycardia—Methylprednisolone—multiple sclerosis	0.000534	0.00296	CcSEcCtD
Lisuride—Malnutrition—Prednisone—multiple sclerosis	0.000531	0.00294	CcSEcCtD
Lisuride—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00053	0.00294	CcSEcCtD
Lisuride—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000529	0.00293	CcSEcCtD
Lisuride—HTR2A—cerebellum—multiple sclerosis	0.000527	0.00162	CbGeAlD
Lisuride—Asthenia—Mitoxantrone—multiple sclerosis	0.000522	0.00289	CcSEcCtD
Lisuride—CYP3A4—nervous system—multiple sclerosis	0.000518	0.0016	CbGeAlD
Lisuride—Anxiety—Betamethasone—multiple sclerosis	0.000518	0.00287	CcSEcCtD
Lisuride—Anxiety—Dexamethasone—multiple sclerosis	0.000518	0.00287	CcSEcCtD
Lisuride—CYP2D6—nervous system—multiple sclerosis	0.00051	0.00157	CbGeAlD
Lisuride—ADRA2A—brain—multiple sclerosis	0.000503	0.00155	CbGeAlD
Lisuride—CYP3A4—central nervous system—multiple sclerosis	0.000499	0.00154	CbGeAlD
Lisuride—Insomnia—Triamcinolone—multiple sclerosis	0.000496	0.00275	CcSEcCtD
Lisuride—Insomnia—Methylprednisolone—multiple sclerosis	0.000495	0.00274	CcSEcCtD
Lisuride—Infection—Dexamethasone—multiple sclerosis	0.000495	0.00274	CcSEcCtD
Lisuride—Infection—Betamethasone—multiple sclerosis	0.000495	0.00274	CcSEcCtD
Lisuride—Feeling abnormal—Prednisolone—multiple sclerosis	0.000492	0.00272	CcSEcCtD
Lisuride—CYP2D6—central nervous system—multiple sclerosis	0.000491	0.00151	CbGeAlD
Lisuride—Dyspnoea—Triamcinolone—multiple sclerosis	0.000489	0.00271	CcSEcCtD
Lisuride—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000488	0.0027	CcSEcCtD
Lisuride—Nervous system disorder—Betamethasone—multiple sclerosis	0.000488	0.0027	CcSEcCtD
Lisuride—Tachycardia—Dexamethasone—multiple sclerosis	0.000486	0.00269	CcSEcCtD
Lisuride—Tachycardia—Betamethasone—multiple sclerosis	0.000486	0.00269	CcSEcCtD
Lisuride—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000481	0.00267	CcSEcCtD
Lisuride—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000481	0.00267	CcSEcCtD
Lisuride—CYP2D6—cerebellum—multiple sclerosis	0.00048	0.00148	CbGeAlD
Lisuride—Vertigo—Prednisone—multiple sclerosis	0.000477	0.00264	CcSEcCtD
Lisuride—Syncope—Prednisone—multiple sclerosis	0.000476	0.00264	CcSEcCtD
Lisuride—Anorexia—Betamethasone—multiple sclerosis	0.000475	0.00263	CcSEcCtD
Lisuride—Anorexia—Dexamethasone—multiple sclerosis	0.000475	0.00263	CcSEcCtD
Lisuride—Cardiac disorder—Methotrexate—multiple sclerosis	0.000473	0.00262	CcSEcCtD
Lisuride—Fatigue—Triamcinolone—multiple sclerosis	0.000473	0.00262	CcSEcCtD
Lisuride—Fatigue—Methylprednisolone—multiple sclerosis	0.000472	0.00261	CcSEcCtD
Lisuride—Angiopathy—Methotrexate—multiple sclerosis	0.000463	0.00256	CcSEcCtD
Lisuride—Vomiting—Mitoxantrone—multiple sclerosis	0.000462	0.00256	CcSEcCtD
Lisuride—Immune system disorder—Methotrexate—multiple sclerosis	0.000461	0.00255	CcSEcCtD
Lisuride—Mediastinal disorder—Methotrexate—multiple sclerosis	0.00046	0.00255	CcSEcCtD
Lisuride—Headache—Mitoxantrone—multiple sclerosis	0.000456	0.00252	CcSEcCtD
Lisuride—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000452	0.0025	CcSEcCtD
Lisuride—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000451	0.0025	CcSEcCtD
Lisuride—Anxiety—Prednisone—multiple sclerosis	0.000451	0.0025	CcSEcCtD
Lisuride—Insomnia—Dexamethasone—multiple sclerosis	0.00045	0.00249	CcSEcCtD
Lisuride—Insomnia—Betamethasone—multiple sclerosis	0.00045	0.00249	CcSEcCtD
Lisuride—Mental disorder—Methotrexate—multiple sclerosis	0.000447	0.00247	CcSEcCtD
Lisuride—Malnutrition—Methotrexate—multiple sclerosis	0.000444	0.00246	CcSEcCtD
Lisuride—Decreased appetite—Dexamethasone—multiple sclerosis	0.000433	0.0024	CcSEcCtD
Lisuride—Decreased appetite—Betamethasone—multiple sclerosis	0.000433	0.0024	CcSEcCtD
Lisuride—Infection—Prednisone—multiple sclerosis	0.000431	0.00239	CcSEcCtD
Lisuride—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.00043	0.00238	CcSEcCtD
Lisuride—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.00043	0.00238	CcSEcCtD
Lisuride—Fatigue—Dexamethasone—multiple sclerosis	0.000429	0.00238	CcSEcCtD
Lisuride—Fatigue—Betamethasone—multiple sclerosis	0.000429	0.00238	CcSEcCtD
Lisuride—HTR2A—brain—multiple sclerosis	0.000428	0.00132	CbGeAlD
Lisuride—Nervous system disorder—Prednisone—multiple sclerosis	0.000425	0.00235	CcSEcCtD
Lisuride—Tachycardia—Prednisone—multiple sclerosis	0.000423	0.00234	CcSEcCtD
Lisuride—Hyperhidrosis—Prednisone—multiple sclerosis	0.000419	0.00232	CcSEcCtD
Lisuride—Anorexia—Prednisone—multiple sclerosis	0.000413	0.00229	CcSEcCtD
Lisuride—Feeling abnormal—Betamethasone—multiple sclerosis	0.00041	0.00227	CcSEcCtD
Lisuride—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00041	0.00227	CcSEcCtD
Lisuride—Vertigo—Methotrexate—multiple sclerosis	0.000399	0.00221	CcSEcCtD
Lisuride—Dizziness—Prednisolone—multiple sclerosis	0.000395	0.00218	CcSEcCtD
Lisuride—Asthenia—Triamcinolone—multiple sclerosis	0.000394	0.00218	CcSEcCtD
Lisuride—Asthenia—Methylprednisolone—multiple sclerosis	0.000393	0.00218	CcSEcCtD
Lisuride—Insomnia—Prednisone—multiple sclerosis	0.000392	0.00217	CcSEcCtD
Lisuride—CYP2D6—brain—multiple sclerosis	0.00039	0.0012	CbGeAlD
Lisuride—Cough—Methotrexate—multiple sclerosis	0.000387	0.00215	CcSEcCtD
Lisuride—Decreased appetite—Prednisone—multiple sclerosis	0.000377	0.00209	CcSEcCtD
Lisuride—Fatigue—Prednisone—multiple sclerosis	0.000374	0.00207	CcSEcCtD
Lisuride—Headache—Prednisolone—multiple sclerosis	0.000374	0.00207	CcSEcCtD
Lisuride—Constipation—Prednisone—multiple sclerosis	0.000371	0.00205	CcSEcCtD
Lisuride—Confusional state—Methotrexate—multiple sclerosis	0.000365	0.00202	CcSEcCtD
Lisuride—Dizziness—Triamcinolone—multiple sclerosis	0.000363	0.00201	CcSEcCtD
Lisuride—Dizziness—Methylprednisolone—multiple sclerosis	0.000362	0.002	CcSEcCtD
Lisuride—Infection—Methotrexate—multiple sclerosis	0.00036	0.00199	CcSEcCtD
Lisuride—Feeling abnormal—Prednisone—multiple sclerosis	0.000357	0.00198	CcSEcCtD
Lisuride—Asthenia—Dexamethasone—multiple sclerosis	0.000357	0.00198	CcSEcCtD
Lisuride—Asthenia—Betamethasone—multiple sclerosis	0.000357	0.00198	CcSEcCtD
Lisuride—Nervous system disorder—Methotrexate—multiple sclerosis	0.000355	0.00197	CcSEcCtD
Lisuride—Hyperhidrosis—Methotrexate—multiple sclerosis	0.00035	0.00194	CcSEcCtD
Lisuride—Vomiting—Triamcinolone—multiple sclerosis	0.000349	0.00193	CcSEcCtD
Lisuride—Vomiting—Methylprednisolone—multiple sclerosis	0.000348	0.00193	CcSEcCtD
Lisuride—Anorexia—Methotrexate—multiple sclerosis	0.000345	0.00191	CcSEcCtD
Lisuride—Headache—Triamcinolone—multiple sclerosis	0.000344	0.0019	CcSEcCtD
Lisuride—Headache—Methylprednisolone—multiple sclerosis	0.000343	0.0019	CcSEcCtD
Lisuride—Dizziness—Betamethasone—multiple sclerosis	0.000329	0.00182	CcSEcCtD
Lisuride—Dizziness—Dexamethasone—multiple sclerosis	0.000329	0.00182	CcSEcCtD
Lisuride—Insomnia—Methotrexate—multiple sclerosis	0.000328	0.00181	CcSEcCtD
Lisuride—Dyspnoea—Methotrexate—multiple sclerosis	0.000323	0.00179	CcSEcCtD
Lisuride—Somnolence—Methotrexate—multiple sclerosis	0.000322	0.00178	CcSEcCtD
Lisuride—Vomiting—Dexamethasone—multiple sclerosis	0.000317	0.00175	CcSEcCtD
Lisuride—Vomiting—Betamethasone—multiple sclerosis	0.000317	0.00175	CcSEcCtD
Lisuride—Decreased appetite—Methotrexate—multiple sclerosis	0.000315	0.00174	CcSEcCtD
Lisuride—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000313	0.00173	CcSEcCtD
Lisuride—Fatigue—Methotrexate—multiple sclerosis	0.000312	0.00173	CcSEcCtD
Lisuride—Headache—Betamethasone—multiple sclerosis	0.000312	0.00173	CcSEcCtD
Lisuride—Headache—Dexamethasone—multiple sclerosis	0.000312	0.00173	CcSEcCtD
Lisuride—Asthenia—Prednisone—multiple sclerosis	0.000311	0.00172	CcSEcCtD
Lisuride—Feeling abnormal—Methotrexate—multiple sclerosis	0.000299	0.00165	CcSEcCtD
Lisuride—Dizziness—Prednisone—multiple sclerosis	0.000287	0.00159	CcSEcCtD
Lisuride—Vomiting—Prednisone—multiple sclerosis	0.000276	0.00153	CcSEcCtD
Lisuride—Headache—Prednisone—multiple sclerosis	0.000272	0.0015	CcSEcCtD
Lisuride—Asthenia—Methotrexate—multiple sclerosis	0.00026	0.00144	CcSEcCtD
Lisuride—Dizziness—Methotrexate—multiple sclerosis	0.00024	0.00133	CcSEcCtD
Lisuride—Vomiting—Methotrexate—multiple sclerosis	0.00023	0.00128	CcSEcCtD
Lisuride—Headache—Methotrexate—multiple sclerosis	0.000227	0.00126	CcSEcCtD
Lisuride—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	2.3e-05	9.29e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCR5—multiple sclerosis	2.28e-05	9.24e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—MAPK1—multiple sclerosis	2.28e-05	9.22e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—POMC—multiple sclerosis	2.28e-05	9.2e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	2.26e-05	9.15e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—MMP9—multiple sclerosis	2.26e-05	9.14e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CD80—multiple sclerosis	2.26e-05	9.13e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL2RA—multiple sclerosis	2.25e-05	9.1e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCR5—multiple sclerosis	2.25e-05	9.09e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—APOE—multiple sclerosis	2.25e-05	9.08e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—IL2—multiple sclerosis	2.23e-05	9.03e-05	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	2.23e-05	9.03e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CD80—multiple sclerosis	2.23e-05	9.01e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CD80—multiple sclerosis	2.23e-05	9.01e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—CCL2—multiple sclerosis	2.23e-05	9e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—APOE—multiple sclerosis	2.22e-05	9e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL2RA—multiple sclerosis	2.22e-05	8.96e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—IL2—multiple sclerosis	2.2e-05	8.89e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	2.2e-05	8.89e-05	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	2.2e-05	8.88e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—BCHE—multiple sclerosis	2.19e-05	8.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	2.18e-05	8.82e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—MAPK1—multiple sclerosis	2.18e-05	8.81e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TYK2—multiple sclerosis	2.15e-05	8.7e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—APOE—multiple sclerosis	2.15e-05	8.68e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—POMC—multiple sclerosis	2.15e-05	8.67e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—APOE—multiple sclerosis	2.14e-05	8.64e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—POMC—multiple sclerosis	2.14e-05	8.63e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—SPP1—multiple sclerosis	2.13e-05	8.61e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TYK2—multiple sclerosis	2.12e-05	8.56e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—POMC—multiple sclerosis	2.12e-05	8.56e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—POMC—multiple sclerosis	2.12e-05	8.56e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CCL2—multiple sclerosis	2.1e-05	8.49e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	2.1e-05	8.48e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	2.09e-05	8.46e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—APOE—multiple sclerosis	2.08e-05	8.4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCR5—multiple sclerosis	2.07e-05	8.38e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CCL2—multiple sclerosis	2.07e-05	8.37e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CCL2—multiple sclerosis	2.07e-05	8.37e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	2.06e-05	8.33e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—MAPK1—multiple sclerosis	2.05e-05	8.3e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—APOE—multiple sclerosis	2.05e-05	8.27e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	2.04e-05	8.26e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	2.04e-05	8.25e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CD80—multiple sclerosis	2.03e-05	8.21e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL2—multiple sclerosis	2.03e-05	8.2e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—MAPK1—multiple sclerosis	2.03e-05	8.19e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—MAPK1—multiple sclerosis	2.03e-05	8.19e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TYK2—multiple sclerosis	2.02e-05	8.17e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—APOE—multiple sclerosis	2.02e-05	8.16e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CD80—multiple sclerosis	2.01e-05	8.13e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	2.01e-05	8.13e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—STAT3—multiple sclerosis	2.01e-05	8.12e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	2e-05	8.08e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.99e-05	8.07e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—ALB—multiple sclerosis	1.95e-05	7.87e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CD80—multiple sclerosis	1.94e-05	7.85e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CD80—multiple sclerosis	1.93e-05	7.81e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—POMC—multiple sclerosis	1.93e-05	7.8e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—POMC—multiple sclerosis	1.91e-05	7.73e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	1.91e-05	7.71e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TYK2—multiple sclerosis	1.91e-05	7.71e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	1.89e-05	7.63e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—APOE—multiple sclerosis	1.89e-05	7.62e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TYK2—multiple sclerosis	1.88e-05	7.6e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TYK2—multiple sclerosis	1.88e-05	7.6e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CD80—multiple sclerosis	1.88e-05	7.6e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CCL2—multiple sclerosis	1.87e-05	7.56e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—MYC—multiple sclerosis	1.87e-05	7.55e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—TGFB1—multiple sclerosis	1.86e-05	7.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.86e-05	7.5e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	1.86e-05	7.5e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CD80—multiple sclerosis	1.85e-05	7.48e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	1.85e-05	7.47e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—POMC—multiple sclerosis	1.85e-05	7.46e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—POMC—multiple sclerosis	1.84e-05	7.42e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—MAPK1—multiple sclerosis	1.83e-05	7.4e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL2—multiple sclerosis	1.83e-05	7.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	1.83e-05	7.39e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—MAPK1—multiple sclerosis	1.83e-05	7.38e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	1.82e-05	7.36e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	1.81e-05	7.34e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.81e-05	7.3e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.8e-05	7.26e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL2—multiple sclerosis	1.79e-05	7.24e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—POMC—multiple sclerosis	1.79e-05	7.22e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	1.78e-05	7.2e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.77e-05	7.14e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL2—multiple sclerosis	1.76e-05	7.12e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.76e-05	7.1e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—POMC—multiple sclerosis	1.76e-05	7.1e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling by GPCR—IL6—multiple sclerosis	1.75e-05	7.09e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCL2—multiple sclerosis	1.75e-05	7.06e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—POMC—multiple sclerosis	1.73e-05	7.01e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	1.73e-05	7e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCL2—multiple sclerosis	1.72e-05	6.95e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	1.71e-05	6.93e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.71e-05	6.91e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CD80—multiple sclerosis	1.7e-05	6.89e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TYK2—multiple sclerosis	1.7e-05	6.87e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	1.69e-05	6.85e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	1.69e-05	6.82e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.68e-05	6.8e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL2—multiple sclerosis	1.68e-05	6.8e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.68e-05	6.78e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—IL6—multiple sclerosis	1.67e-05	6.77e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MMP9—multiple sclerosis	1.67e-05	6.74e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	1.64e-05	6.63e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	1.63e-05	6.59e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—POMC—multiple sclerosis	1.62e-05	6.55e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—POMC—multiple sclerosis	1.59e-05	6.44e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MMP9—multiple sclerosis	1.59e-05	6.44e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL2—multiple sclerosis	1.59e-05	6.41e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TYK2—multiple sclerosis	1.59e-05	6.41e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCL2—multiple sclerosis	1.59e-05	6.41e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—ALB—multiple sclerosis	1.58e-05	6.39e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—IL6—multiple sclerosis	1.58e-05	6.38e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL2—multiple sclerosis	1.57e-05	6.33e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL2—multiple sclerosis	1.57e-05	6.33e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TYK2—multiple sclerosis	1.56e-05	6.31e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	1.56e-05	6.31e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—IL6—multiple sclerosis	1.56e-05	6.3e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—IL6—multiple sclerosis	1.56e-05	6.3e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	1.55e-05	6.27e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	1.54e-05	6.22e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	1.53e-05	6.17e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.53e-05	6.17e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	1.51e-05	6.09e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MMP9—multiple sclerosis	1.5e-05	6.07e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—STAT3—multiple sclerosis	1.48e-05	5.99e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MMP9—multiple sclerosis	1.48e-05	5.99e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MMP9—multiple sclerosis	1.48e-05	5.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	1.45e-05	5.86e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TYK2—multiple sclerosis	1.44e-05	5.82e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MYC—multiple sclerosis	1.43e-05	5.78e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.43e-05	5.78e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	1.43e-05	5.77e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL2—multiple sclerosis	1.43e-05	5.77e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	1.42e-05	5.74e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	1.42e-05	5.74e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	1.42e-05	5.73e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—STAT3—multiple sclerosis	1.42e-05	5.72e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL2—multiple sclerosis	1.41e-05	5.71e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—IL6—multiple sclerosis	1.41e-05	5.68e-05	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—IL6—multiple sclerosis	1.4e-05	5.67e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MYC—multiple sclerosis	1.4e-05	5.66e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	1.4e-05	5.66e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	1.4e-05	5.65e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.39e-05	5.61e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MYC—multiple sclerosis	1.38e-05	5.57e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TGFB1—multiple sclerosis	1.37e-05	5.56e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	1.37e-05	5.54e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL2—multiple sclerosis	1.36e-05	5.51e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	1.36e-05	5.49e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL2—multiple sclerosis	1.36e-05	5.49e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	1.35e-05	5.46e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	1.35e-05	5.46e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK1—multiple sclerosis	1.35e-05	5.45e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MMP9—multiple sclerosis	1.34e-05	5.41e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—STAT3—multiple sclerosis	1.33e-05	5.4e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL2—multiple sclerosis	1.32e-05	5.34e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—multiple sclerosis	1.32e-05	5.32e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—multiple sclerosis	1.32e-05	5.32e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—APOE—multiple sclerosis	1.32e-05	5.32e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—multiple sclerosis	1.32e-05	5.32e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—IL6—multiple sclerosis	1.31e-05	5.31e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TGFB1—multiple sclerosis	1.31e-05	5.3e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL2—multiple sclerosis	1.3e-05	5.25e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—IL6—multiple sclerosis	1.29e-05	5.23e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	1.29e-05	5.22e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	1.29e-05	5.21e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK1—multiple sclerosis	1.29e-05	5.2e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	1.28e-05	5.19e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—multiple sclerosis	1.25e-05	5.05e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—multiple sclerosis	1.24e-05	5.01e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TGFB1—multiple sclerosis	1.24e-05	5e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—multiple sclerosis	1.23e-05	4.97e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—multiple sclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—multiple sclerosis	1.22e-05	4.95e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TGFB1—multiple sclerosis	1.22e-05	4.94e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TGFB1—multiple sclerosis	1.22e-05	4.94e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK1—multiple sclerosis	1.21e-05	4.91e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	1.2e-05	4.85e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—multiple sclerosis	1.2e-05	4.84e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK1—multiple sclerosis	1.2e-05	4.84e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK1—multiple sclerosis	1.2e-05	4.84e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—multiple sclerosis	1.19e-05	4.82e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—multiple sclerosis	1.19e-05	4.81e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—multiple sclerosis	1.18e-05	4.76e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	1.17e-05	4.74e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	1.15e-05	4.64e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	1.14e-05	4.62e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—multiple sclerosis	1.13e-05	4.58e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—POMC—multiple sclerosis	1.13e-05	4.57e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	1.12e-05	4.51e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—multiple sclerosis	1.12e-05	4.51e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	1.11e-05	4.5e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—multiple sclerosis	1.11e-05	4.49e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—multiple sclerosis	1.1e-05	4.47e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TGFB1—multiple sclerosis	1.1e-05	4.46e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—multiple sclerosis	1.09e-05	4.42e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	1.09e-05	4.41e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK1—multiple sclerosis	1.08e-05	4.37e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—multiple sclerosis	1.07e-05	4.35e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	1.07e-05	4.33e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	1.07e-05	4.31e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—multiple sclerosis	1.07e-05	4.31e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	1.06e-05	4.3e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—multiple sclerosis	1.06e-05	4.29e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	1.06e-05	4.28e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—multiple sclerosis	1.05e-05	4.26e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	1.04e-05	4.22e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	1.04e-05	4.2e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—multiple sclerosis	1.04e-05	4.19e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—multiple sclerosis	1.03e-05	4.17e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—ALB—multiple sclerosis	1.03e-05	4.17e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TGFB1—multiple sclerosis	1.03e-05	4.16e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—multiple sclerosis	1.02e-05	4.11e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	1.01e-05	4.1e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TGFB1—multiple sclerosis	1.01e-05	4.1e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK1—multiple sclerosis	1.01e-05	4.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—multiple sclerosis	1.01e-05	4.07e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK1—multiple sclerosis	9.94e-06	4.02e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	9.92e-06	4.01e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—multiple sclerosis	9.89e-06	4e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—multiple sclerosis	9.36e-06	3.79e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	9.34e-06	3.78e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—multiple sclerosis	9.32e-06	3.77e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—multiple sclerosis	9.21e-06	3.73e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—multiple sclerosis	9.2e-06	3.72e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—multiple sclerosis	9.2e-06	3.72e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	9.19e-06	3.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	9.16e-06	3.7e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	9.02e-06	3.65e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	9.01e-06	3.64e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—APOE—multiple sclerosis	8.6e-06	3.48e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	8.38e-06	3.39e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—multiple sclerosis	8.38e-06	3.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	8.36e-06	3.38e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—multiple sclerosis	8.31e-06	3.36e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	8.2e-06	3.32e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—multiple sclerosis	8.02e-06	3.24e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—multiple sclerosis	7.98e-06	3.22e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—multiple sclerosis	7.76e-06	3.14e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—multiple sclerosis	7.64e-06	3.09e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—POMC—multiple sclerosis	7.39e-06	2.99e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—multiple sclerosis	7.04e-06	2.85e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—multiple sclerosis	6.93e-06	2.8e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ALB—multiple sclerosis	6.74e-06	2.72e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	6.3e-06	2.55e-05	CbGpPWpGaD
